Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP ... significant and clinically ...

Expert says, that by recognising the connection between seasonal changes, allergies, and sinus health, individuals can take ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.

compared to a placebo in adults with severe chronic rhinosinusitis with nasal polyps, showed a "statistically significant and ...

A deviated septum occurs when you have two different-sized nasal passageways which can cause one-sided congestion.

While those with pre-existing conditions like chronic obstructive pulmonary disease (COPD ... "Post-Covid, many people have lingering lung issues which reduces their capacity to cope with pollution.

Aggarwal said such patients are experiencing a drop in oxygen saturation and breathing difficulties due to the rising ...